Serum YKL-40 levels as a novel marker of inflammation in patients with endometriosis

article OA: bronze CC0 ⤵ 8 in-corpus citations
AI-generated summary by claude@2026-06, 2026-06-08

Serum YKL-40 levels were significantly elevated in patients with endometriosis compared to healthy controls, suggesting its potential as a novel biomarker.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

PURPOSE: To establish serum YKL-40 concentrations in patients with endometriosis compared to age-matched healthy subjects. MATERIALS AND METHODS: This was a cross-sectional clinical study conducted in a tertiary care center. Demographics and serum YKL levels were determined and noted in a total of 63 cases (33 endometriosis patients, 30 healthy controls). Measurement of YKL-40 levels was made using a YKL-40 enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer's protocol. RESULTS: The mean serum YKL-40 levels of the patient group was 106.0 +/- 15.9 (range 23.44 to 382.55) years, while the mean serum YKL-40 levels of the controls was 52.2 +/- 7.0 (range 22.35 to 160.0) years (p = 0.003). CONCLUSIONS: This is the first study evaluating serum YKL-40 levels in endometriosis. The present results indicate that YKL-40 levels were increased in patients with endometriosis compared to controls. The authors propose that circulating YKL-40 levels could be a novel biomarker for diagnosis and follow-up of endometriosis.
Full text 1,698 characters · extracted from oa-doi-fallback · 2 sections · click to expand

Abstract

Purpose: To establish serum YKL-40 concentrations in patients with endometriosis compared to age-matched healthy subjects. Materials and Methods: This was a cross-sectional clinical study conducted in a tertiary care center. Demographics and serum YKL levels were determined and noted in a total of 63 cases (33 endometriosis patients, 30 healthy controls). Measurement of YKL-40 levels was made using a YKL-40 enzyme-linked immunosorbent assay (ELISA) kit according to the manufacturer’s protocol. Results: The mean serum YKL-40 levels of the patient group was 106.0 ± 15.9 (range 23.44 to 382.55) years, while the mean serum YKL-40 levels of the controls was 52.2 ± 7.0 (range 22.35 to 160.0) years (p = 0.003). Conclusions: This is the first study evaluating serum YKL-40 levels in endometriosis. The present results indicate that YKL-40 levels were increased in patients with endometriosis compared to controls. The authors propose that circulating YKL-40 levels could be a novel biomarker for diagnosis and follow-up of endometriosis.

Keywords

- Endometriosis - Serum - YKL-40 levels - Marker

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Adipokines Biomarkers Endometriosis Lectins Adipokines Adipokines Adult Biomarkers Case-Control Studies Chitinase-3-Like Protein 1 Cross-Sectional Studies Endometriosis Enzyme-Linked Immunosorbent Assay Female Humans Lectins Lectins

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (27)

Cited by (8)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-04T00:00:01.174412+00:00
pubmed
last seen: 2026-05-13T22:17:39.907309+00:00
License: CC0 · commercial use OK